Hot Summer. Cool Savings. | Start Saving >>
12017
Everolimus

Everolimus #12017

Western Blotting

Western blot analysis of extracts from HeLa cells, serum-starved overnight and treated with hIGF-I #8917 (100 ng/ml, 10 min) either with or without Everolimus pretreatment (1 hr) at the indicated concentrations, using Phospho-p70 S6 Kinase (Thr389) Antibody #9205 (upper) or p70 S6 Kinase (49D7) Rabbit mAb #2708 (lower).

Learn more about how we get our images
Western Blotting

Western blot analysis of extracts from HeLa cells, serum-starved overnight and treated with hIGF-I #8917 (100 ng/ml, 10 min) either with or without Everolimus pretreatment (1 hr) at the indicated concentrations, using Phospho-S6 Ribosomal Protein (Ser235/236) (D57.2.2E) XP® Rabbit mAb #4858 (upper) or S6 Ribosomal Protein (5G10) Rabbit mAb #2217 (lower).

Learn more about how we get our images
Structure

Chemical structure of everolimus.

Learn more about how we get our images

Everolimus is supplied as a lyophilized powder. For a 1 mM stock, reconstitute the 1 mg in 1.04 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 10-100 nM either as a pretreatment for 0.5-1 hr prior to treating with a stimulator or is used alone with varying treatment times lasting up to 24 hr. Soluble in DMSO or ethanol at 100 mg/ml; very poorly soluble in water with maximum solubility ~1-10 µM.

Storage:

Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Molecular Weight:

958.22 g/mol

Purity:

>99%

Molecular Formula:

C53H83NO14

Everolimus, also known as RAD001, is an immunosuppressant analog of rapamycin. Everolimus forms a complex with FKBP12 with an IC50 = ~2 nM in FK506 competitive binding assays (1,2), and this complex then binds to and inhibits mTORC1 (3). Studies have shown that everolimus treatment of cells can lead to the dephosphorylation of mTOR downstream targets (4-7), inhibition of VEGF- and bFRF-stimulated proliferation in HUVE cells (6), and reduction of hypoxia-induced HIF-1 protein levels (7).

  1. Sedrani, R. et al. (1998) Transplant Proc 30, 2192-4.
  2. Schuler, W. et al. (1997) Transplantation 64, 36-42.
  3. Houghton, P.J. (2010) Clin Cancer Res 16, 1368-72.
  4. Rosich, L. et al. (2012) Clin Cancer Res 18, 5278-89.
  5. Cao, C. et al. (2006) Cancer Res 66, 10040-7.
  6. Lane, H.A. et al. (2009) Clin Cancer Res 15, 1612-22.
  7. Knaup, K.X. et al. (2009) Mol Cancer Res 7, 88-98.
For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

To Purchase # 12017S

View sizes
Product # Size Price
12017S
1 mg $ 30.0